Shanghai Haohai Biological Technology Co., Ltd.
Climate Impact & Sustainability Data (2019)
Reporting Period: 2019
Environmental Metrics
ESG Focus Areas
- Environmental
- Social
- Governance
Environmental Achievements
- Completed a certification on environmental management system.
- All infrastructure projects located inside China have strictly implemented the “Three Simultaneous ” environmental protection policy.
Social Achievements
- The quality management of products covers the entire lifecycle of the pharmaceutical product.
- Various thematic training programs for its employees regularly, such as training in relation to the knowledge of the product and sales of the Group, the applicable laws and regulations for operations, the requirements of GMP certificate, quality control, workplace safety and corporate culture.
Governance Achievements
- The Company has complied with all applicable code provisions under the Corporate Governance Code.
- The Company has adopted the Model Code as the code of conduct regarding securities transactions by the Directors and Supervisors of the Company.
Climate Goals & Targets
Environmental Challenges
- Severe challenges in operating results of pharmaceutical and medical device industry as affected by the reform of medical insurance payment methods, centralized tendering and procurement with target quantity.
- The Group’s sales volume and sales unit price of HA dermal filler products decreased as affected by the periodic industry rectification in the end market of medical aesthetics and the significant decrease in the selling price of competing HA dermal filler products.
- The overall gross profit margin of the Group was 77.19%, representing a slight decrease as compared to 78.37% in 2018, mainly due to the smaller proportion of HA Dermal Filler products in the Group’s total revenue, which have higher gross profit margin.
Mitigation Strategies
- The Group focused on increasing investment in R&D and advancing service upgrade so as to secure the steady growth of the entire principal business.
- Actively adjusted its sales strategy and maintained a relatively stable and good overall price system with a series of effective professional market service measures.
- The Group continued to deepen the integration of industrial chain for ophthalmology cataract treatment business and focused on the resource rationalization and optimization of marketing channels.